Natera (NASDAQ:NTRA) Price Target Raised to $200.00

Natera (NASDAQ:NTRA - Free Report) had its price objective upped by Piper Sandler from $150.00 to $200.00 in a research report report published on Monday,Benzinga reports. Piper Sandler currently has an overweight rating on the medical research company's stock.

Several other research analysts have also recently weighed in on NTRA. Morgan Stanley increased their price objective on Natera from $132.00 to $176.00 and gave the stock an "overweight" rating in a research report on Thursday. Robert W. Baird lifted their price objective on shares of Natera from $120.00 to $160.00 and gave the stock an "outperform" rating in a research note on Wednesday, November 13th. StockNews.com downgraded shares of Natera from a "hold" rating to a "sell" rating in a report on Thursday. Stephens reaffirmed an "overweight" rating and set a $125.00 target price on shares of Natera in a report on Friday, August 9th. Finally, Sanford C. Bernstein boosted their price target on Natera from $125.00 to $135.00 and gave the company an "outperform" rating in a research note on Wednesday, October 30th. One analyst has rated the stock with a sell rating and seventeen have issued a buy rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $140.59.

Natera Stock Performance

Shares of NASDAQ NTRA traded up $7.36 during midday trading on Monday, hitting $153.42. 1,761,089 shares of the company's stock were exchanged, compared to its average volume of 1,340,585. The company has a quick ratio of 4.01, a current ratio of 4.39 and a debt-to-equity ratio of 0.33. The firm has a market capitalization of $20.25 billion, a PE ratio of -87.17 and a beta of 1.53. Natera has a 12 month low of $53.31 and a 12 month high of $167.79. The company's 50 day moving average price is $127.38 and its 200 day moving average price is $115.76.

Natera (NASDAQ:NTRA - Get Free Report) last announced its earnings results on Tuesday, November 12th. The medical research company reported ($0.26) EPS for the quarter, topping the consensus estimate of ($0.57) by $0.31. The business had revenue of $439.80 million during the quarter, compared to the consensus estimate of $361.43 million. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. Natera's revenue was up 63.9% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.95) EPS. As a group, analysts predict that Natera will post -1.7 earnings per share for the current fiscal year.

Insider Activity

In other news, Director Gail Boxer Marcus sold 2,212 shares of the business's stock in a transaction that occurred on Thursday, November 14th. The shares were sold at an average price of $158.53, for a total value of $350,668.36. Following the transaction, the director now owns 19,386 shares in the company, valued at approximately $3,073,262.58. The trade was a 10.24 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Steven Leonard Chapman sold 4,728 shares of the stock in a transaction on Friday, November 15th. The stock was sold at an average price of $146.41, for a total transaction of $692,226.48. Following the sale, the chief executive officer now owns 185,034 shares of the company's stock, valued at approximately $27,090,827.94. This trade represents a 2.49 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 36,821 shares of company stock valued at $4,776,878. Insiders own 7.60% of the company's stock.

Institutional Trading of Natera

A number of institutional investors have recently bought and sold shares of NTRA. Russell Investments Group Ltd. boosted its position in shares of Natera by 15.1% during the 1st quarter. Russell Investments Group Ltd. now owns 74,460 shares of the medical research company's stock valued at $6,810,000 after purchasing an additional 9,781 shares in the last quarter. Vanguard Group Inc. grew its position in shares of Natera by 0.7% during the 1st quarter. Vanguard Group Inc. now owns 11,044,743 shares of the medical research company's stock worth $1,010,152,000 after buying an additional 72,848 shares during the period. O Shaughnessy Asset Management LLC bought a new stake in shares of Natera in the 1st quarter valued at $220,000. Natixis acquired a new position in shares of Natera during the 1st quarter valued at $758,000. Finally, Castle Hook Partners LP bought a new position in Natera during the first quarter worth $14,498,000. Institutional investors own 99.90% of the company's stock.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.